Sciatic nerve

ORYZON Reports Financial Results and Corporate Update for Quarter Ended December 31, 2023

Retrieved on: 
Monday, February 26, 2024
Borderline personality disorder, HOPE, HDAC6, National Cancer Institute, EVOLUTION, CMT, Agitation, Data analysis, Convertible bond, ICIS, ALS, SCLC, Azacitidine, Duration, ICI, IIS, Sciatic nerve, Deficit spending, Paclitaxel, DSM-IV codes, Development, Genomics, ALS Association, FMS, LSD1, AML, Clinical Global Impression, MSKCC, Conference, Aggression, Safety, Biomarker, CNS, Venetoclax, CRADA, OHSU, MRD, Clinical trial, BPD, Measure (mathematics), IND, FCCC, Dor, Human, Innovation, EMA, Kabuki syndrome, NET, NCI, Aes, Glomus tumor, FDA, GST, Food, Platinum, Schizophrenia, Phase II, Charcot–Marie–Tooth disease, Medicine, Patient, BEST, Disease, Pharmaceutical industry

Dr Carlos Buesa, Oryzon’s Chief Executive Officer, said: “Oryzon continued with a strong path in its clinical programs in the fourth quarter.

Key Points: 
  • Dr Carlos Buesa, Oryzon’s Chief Executive Officer, said: “Oryzon continued with a strong path in its clinical programs in the fourth quarter.
  • Research and development (R&D) expenses were $3.9 and $16.6 million for the quarter and twelve months ended December 31, 2023, respectively, compared to $5.0 and $18.1 million for the quarter and twelve months ended December 31, 2022.
  • General and administrative expenses were $1.2 and $4.2 million for the quarter and twelve months ended December 31, 2023, respectively, compared to $1.2 and $4.8 million for the quarter and twelve months ended December 31, 2022.
  • Net losses were $1.4 and $5.0 million for the quarter and twelve months ended December 31, 2023, respectively, compared to $1.6 and $5.9 million for the quarter and twelve months ended December 31, 2022.

Harvard MedTech Celebrates 2023 Comp Laude® Injured Worker Honoree Ronan McEvoy

Retrieved on: 
Thursday, November 16, 2023
Wearables, Mobile Technology, Technology, Mental Health, Medical Devices, Neurology, Health Technology, Telemedicine, Virtual Medicine, Physical Therapy, Health, Harvard University, Human, Back injury, Sleep, Brain, Depression, Post-traumatic stress disorder, Award, Pain management, Patient, Virtual reality, Mevalonate pathway, Oxycodone, Anxiety, Comp, Trauma, PTSD, Pain, Laminectomy, Electricity, Sciatic nerve, Quality of life, Rónán, Thought

The 2023 Comp Laude® Awards has selected Harvard MedTech patient Ronan McEvoy as an Injured Worker Honoree, as announced Tuesday in a virtual ceremony.

Key Points: 
  • The 2023 Comp Laude® Awards has selected Harvard MedTech patient Ronan McEvoy as an Injured Worker Honoree, as announced Tuesday in a virtual ceremony.
  • Ronan McEvoy was working as a successful restaurant manager when he suffered a serious back injury after moving a heavy object.
  • As a result, he relied on 10mg doses of Oxycodone up to three to four times a day to manage his pain.
  • It wasn’t until his neurosurgeon recommended Vx® Therapy, offered by Harvard MedTech, that he finally found relief.

ORYZON Reports Financial Results and Corporate Updates for Quarter Ended September 30, 2023

Retrieved on: 
Friday, October 27, 2023
Research, ORY, Fruit, DMC, Food, Deficit spending, Risk, Medicine, ECNP, Schizophrenia, Platinum, ICMJE recommendations, SCLC, Charcot–Marie–Tooth disease, Sciatic nerve, Psychotherapy, Paclitaxel, NET, FCCC, MRD, Safety, EVOLUTION, BPD, Kabuki syndrome, Patient, Borderline personality disorder, ALS, Fox Chase Cancer Center, Genomics, Human, Duration, Glomus tumor, Measure (mathematics), Clinical trial, Dor, DSM-IV codes, Animal, European College of Neuropsychopharmacology, LSD1, FMS, CMT, FDA, IND, Innovation, ISIN, CNS, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, R, HOPE, AML, Failure, Medical device, Pharmaceutical industry, Nursing, Cryptocurrency, EU, Science

Dr Carlos Buesa, Oryzon’s Chief Executive Officer, said: “Oryzon continued with a strong path in its clinical programs in the third quarter.

Key Points: 
  • Dr Carlos Buesa, Oryzon’s Chief Executive Officer, said: “Oryzon continued with a strong path in its clinical programs in the third quarter.
  • The company has started a structured dialogue with corporate pharma to identify a suitable partner to move forward the asset to Phase III, pending positive results.
  • General and administrative expenses were $0.7 and $2.9 million for the quarter and nine months ended September 30, 2023, respectively, compared to $0.7 and $3.3 million for the quarter and nine months ended September 30, 2022.
  • Net losses were $0.8 and $3.4 million for the quarter and nine months ended September 30, 2023, respectively, compared to $0.7 and $3.9 million for the quarter and nine months ended September 30, 2022.

Positive Preclinical Data of ORY-4001 for the Treatment of Charcot-Marie-Tooth (CMT) Disease Presented at the 2023 Peripheral Nerve Society (PNS) Annual Meeting

Retrieved on: 
Wednesday, June 21, 2023
Genomics, HDAC, Charcot–Marie–Tooth disease, Diabetic neuropathy, DSM-IV codes, ALS, CMT, Sciatic nerve, Hemotoxin, Sympathetic nervous system, HDAC6, Degenerative disease, ORY, Animal, ISIN, IND, Pharmacology, Pharmaceutical industry

ORY-4001 treatment was able to reverse disease progression symptoms in a Charcot-Marie-Tooth (CMT) mice model.

Key Points: 
  • ORY-4001 treatment was able to reverse disease progression symptoms in a Charcot-Marie-Tooth (CMT) mice model.
  • Notably, ORY-4001 was able to improve myelination and restore axon integrity in the sciatic nerve, and improved compound muscle action potential and nerve conduction in comparison with untreated animals.
  • We are exploring with the CMT community how we can expedite this program to the clinic.”
    CMT is a progressive, degenerative disease involving the peripheral nerves.
  • CMT1A is the most prevalent form, accounting for approximately half of all people with CMT.

Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of ATH-1105 in ALS at the 33rd International Symposium on ALS/MND

Retrieved on: 
Monday, December 5, 2022
Neuroprotection, Sciatic nerve, Inflammation, Research, Communication, Nature, Security (finance), AFL, ALS, NCV, Axon, Safety, Amyotrophic lateral sclerosis, Histology, Biomarker, Athira Pharma, Doctor of Philosophy, International Symposium on Graph Drawing, Maritime Transportation Security Act of 2002, Neurodegeneration, IL-6, Human, CMAP, Plasma, Disease, Neuroinflammation, Dementia, Investment, Lewy body, COVID-19, Patient, Management, Pharmaceutical industry, L. Athira Krishna

BOTHELL, Wash., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today presented data highlighting the potential therapeutic benefits of ATH-1105, a small molecule positive modulator of the HGF/MET neurotrophic system, in a preclinical mouse model of amyotrophic lateral sclerosis (ALS). The findings were presented at the Motor Neurone Disease Association’s 33rd International Symposium on ALS/MND.

Key Points: 
  • The findings were presented at the Motor Neurone Disease Association’s 33rd International Symposium on ALS/MND.
  • Athira aims to provide rapid cognitive improvement and alter the course of neurological diseases with its novel mechanism of action.
  • These forward-looking statements speak only as of the date hereof and Athira undertakes no obligation to update forward-looking statements.
  • Athira may not actually achieve the plans, intentions, or expectations disclosed in its forward-looking statements, and you should not place undue reliance on the forward-looking statements.

Camizestrant Significantly Delayed Disease Progression in Advanced ER-Positive Breast Cancer, Adding at Least 3.5 Months Benefit Versus FASLODEX® (fulvestrant)

Retrieved on: 
Thursday, December 8, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, QT, Hypersensitivity, ESR1, Hypocalcemia, Peripheral neuropathy, Anemia, Angioedema, Headache, AstraZeneca, Syncope, Woman, Duane syndrome, Hives, Xeroderma, Paced Auditory Serial Addition Test, Leukopenia, Sciatic nerve, Risk, Indigestion, Thrombocytopenia, Lung, Rash, Myalgia, Liver, Fatigue, Pain, Back pain, US Foods, Photopsia, Birth, Immunoassay, Constipation, Hair, Infant, Infection, Food, Neutropenia, Bleeding, Bradycardia, Pregnancy, Dysgeusia, Cough, Diarrhea, Estradiol, Itch, PFS, Tears, Neuralgia, CI, Purging disorder, Grade, Mutation, Xerostomia, Vertigo, Patient, Fulvestrant, Nausea, Vomiting, Incidence, Aromatase, Breathe Me, Arthralgia, Erythema, Bone pain, Stomatitis, Weakness, Sciatica, Fetus, Neuropathic pain, Appetite, Pharmaceutical industry, Vaccine, Dietary supplement, Fever

AstraZeneca has a broad clinical development program for camizestrant in advanced breast cancer.

Key Points: 
  • AstraZeneca has a broad clinical development program for camizestrant in advanced breast cancer.
  • Advise women of reproductive potential to use effective contraception during FASLODEX treatment and for 1 year after the last dose.
  • SERENA-2 is a randomized, open-label, parallel group, multicenter Phase II trial evaluating camizestrant at several dose levels compared to FASLODEX in advanced ER-positive, HER2-negative breast cancer.
  • The primary endpoints are PFS defined by response evaluation criteria in solid tumors (RECIST) version 1.1 for 75mg camizestrant versus FASLODEX and for 150mg camizestrant versus FASLODEX.

Capivasertib Plus FASLODEX® (fulvestrant) Reduced the Risk of Disease Progression or Death by 40% Versus FASLODEX in Advanced HR-Positive Breast Cancer

Retrieved on: 
Thursday, December 8, 2022
Oncology, Health, General Health, Clinical Trials, Pharmaceutical, Cardiology, Biotechnology, QT, Indigestion, Thrombocytopenia, ORR, Hypersensitivity, Neutropenia, Rash, Bleeding, Xerostomia, Pregnancy, Dysgeusia, Cough, Hypocalcemia, Vertigo, Patient, Diarrhea, Peripheral neuropathy, Estradiol, OS, Myalgia, Anemia, Liver, Angioedema, Itch, Nausea, Fulvestrant, Neuralgia, Headache, Tears, Fatigue, Vomiting, Syncope, Pain, Back pain, Appetite, Breathe Me, Woman, Incidence, Arthralgia, Erythema, Bone pain, Birth, Stomatitis, Duane syndrome, Hives, Immunoassay, Constipation, Safety, Purging disorder, Hair, Xeroderma, Infant, Sciatica, Weakness, Paced Auditory Serial Addition Test, Infection, Fetus, Leukopenia, AES, Neuropathic pain, Sciatic nerve, Risk, Medical imaging, Vaccine, Dietary supplement, Fever

CAPItello-291 is evaluating the efficacy of capivasertib in combination with FASLODEX versus placebo plus FASLODEX for the treatment of locally advanced (inoperable) or metastatic HR-positive, HER2-low or negative breast cancer.

Key Points: 
  • CAPItello-291 is evaluating the efficacy of capivasertib in combination with FASLODEX versus placebo plus FASLODEX for the treatment of locally advanced (inoperable) or metastatic HR-positive, HER2-low or negative breast cancer.
  • Capivasertib is an investigational oral treatment currently in Phase III trials for the treatment of multiple subtypes of breast cancer, prostate cancer and a Phase II trial for hematologic malignancies.
  • Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION).
  • Comparative Overall Survival of CDK4/6 Inhibitors Plus Endocrine Therapy vs. Endocrine Therapy Alone for Hormone receptor-positive, HER2-negative metastatic breast cancer.

Adial Pharmaceuticals Announces Positive In Vivo Data for Purnovate’s PNV-5030 as a Potential Treatment for Chronic Pain

Retrieved on: 
Monday, September 26, 2022
Sciatic nerve, Adial, Virginia, GLOBE, Pain, APAP, RATS, Pressure, Chronic pain, Paracetamol, NASDAQ, Pharmaceutical industry

At 60 minutes post dose, PNV-5030 reduced pain by 76% compared to the control group (5.3g vs 1.8g, respectively, p

Key Points: 
  • At 60 minutes post dose, PNV-5030 reduced pain by 76% compared to the control group (5.3g vs 1.8g, respectively, p
  • This data further reinforces prior in vivo data demonstrating similar outcomes in treating other types of pain.
  • "PNV-5030 has demonstrated compelling data in animal models of both acute and chronic pain," said William Stilley, CEO of Purnovate.
  • The forward-looking statements include statements regarding Purnovates PNV-5030 as a potential treatment for chronic pain, namely PNV-5030s potential to significantly reduce pain compared to both placebo and acetaminophen.

Poxel Announces the Publication of Two Preclinical Articles on X-Linked Adrenoleukodystrophy for PXL065 and PXL770

Retrieved on: 
Tuesday, July 5, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Diagnosis, NASH, Patient, ABCD1, HSCT, Gait, Growth, Company, Lists of diseases, Haemophilia, Pioglitazone, Euronext Paris, AMPK, Therapy, AMN, Spinal cord, White matter, Fatty liver disease, Metabolic disorder, TZD, Prevalence, Woman, Chronic inflammatory demyelinating polyneuropathy, Journal of Inherited Metabolic Disease, Experiment, Brain, Journal of Pharmacology and Experimental Therapeutics, Degenerative disease, Phenotype, Man, Peroxisome, Inflammation, Peripheral nervous system, Partnership, Weakness, Adrenoleukodystrophy, POC, Sciatic nerve, Cell, Adenosine, Death, Hematopoietic stem cell transplantation, Journal, Incontinence, VLCFA, Metabolism, Disease, Plasma, ALD, Publication, Risk, Pathology, Pharmaceutical industry, Medical device, Imeglimin, Euronext, Pharmacology

POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announces the publication of two preclinical articles on X-Linked Adrenoleukodystrophy (ALD) for PXL065 and PXL770.

Key Points: 
  • POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announces the publication of two preclinical articles on X-Linked Adrenoleukodystrophy (ALD) for PXL065 and PXL770.
  • An article on PXL065 has been published in The Journal of Inherited Metabolic Disease (JIMD) and is entitled Therapeutic potential of deuterium-stabilized (R)-pioglitazone - PXL065 - for X-linked adrenoleukodystrophy.
  • These publications describe similar beneficial preclinical profiles of PXL770 and PXL065 in models of ALD.
  • Listed on Euronext Paris, Poxel is headquartered in Lyon, France, and has subsidiaries in Boston, MA, and Tokyo, Japan.

Karben Wallet - A Wallet That Gives Full Protection From Theft & Deformation

Retrieved on: 
Friday, April 15, 2022
Carbon, Lockheed Martin F-35 Lightning II, Lockheed Martin, Aluminium, RFID, Steel, Suite, Spine, Radio, Karben, Mark (given name), RADIUS, Pelvis, Sciatic nerve, Lockheed, Theft, NFC, Cryptocurrency

NEW CASTLE, Del., April 15, 2022 /PRNewswire/ -- Karben Wallet is a contemporary spin on the classic leather or nylon wallet.

Key Points: 
  • NEW CASTLE, Del., April 15, 2022 /PRNewswire/ -- Karben Wallet is a contemporary spin on the classic leather or nylon wallet.
  • Karben Wallet was recently introduced by the team at YEHYEH Limited to protect wallets from theft and deformation.
  • The Karben Wallet is a wallet made of carbon fiber and aluminum that promotes attractiveness while also protecting users from theft.
  • The Karben Wallet features a sophisticated industrial style that looks equally at home in a museum as it does in the pocket.